Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.26, $0.05 better than the analyst estimate of $0.21. Revenue for the quarter came in at $190.2 million versus the consensus estimate of $183.38 million.

• Total Revenues of $190.2 Million Up 7 Percent
• GAAP Diluted EPS of $1.15 and Adjusted EPS of $0.26 Up 13 Percent
• GeneSight® Demonstrates Statistical Significance for Response and Remission in Prospective Study

GUIDANCE:

Myriad Genetics sees FY2018 EPS of $1.00-$1.05, versus the consensus of $1.03.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.